ASX ANNOUNCEMENT
BENITEC BIOPHARMA (ASX: BLT; OTC: BTEBD)
25 June 2015
Sydney, Australia: Benitec Biopharma is pleased to advise that following review by the Data Safety Monitoring Board (DSMB) of safety data from the three patients dosed in Cohort 2 of the company's Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, the first patient in Cohort 3 has been dosed. This indicates that there have been no serious drug related adverse events in the Cohort 2 patients, in line with pre-clinical expectations.
This patient is the sixth patient to be dosed in the trial, and received a dose of TT-034 representing a concentration 3.125 times higher than the dose administered to patients in Cohort 2.
As with previous patient cohorts, the patient will now be monitored for six weeks, and the data will then be reviewed by the DSMB before progressing to dosing the next patient(s) in Cohort 3. The three clinical trial sites enrolled for the study are currently screening additional patients for inclusion in Cohort 3 in anticipation of the DSMB's review.
Benitec advises that it expects to report data from Cohort 3 patients in Q4 CY15 following completion of all patient dosing and monitoring for the cohort, in line with timelines previously advised to the market.
More detail on the TT-034 trial
TT-034 is a ddRNAi-based therapeutic, designed to treat and potentially cure hepatitis C (HCV) with a single administration. TT-034 targets the hepatitis C viral RNA at three separate, highly conserved sites. As such it acts as a "triple therapy" even though it is a monotherapy, and minimises the ability of the virus to mutate and escape the therapy. Once it reaches the liver cells it enters the nucleus and produces three separate short hairpin RNAs continuously for the life time of the cell. Thus it has the potential to not only treat the existing HCV infection but to guard against reinfection for months to years without the need to re-treat. It has been extensively tested in pre-clinical in vivo studies and no adverse effects were seen at any therapeutic dose. However, as it is regulated as a gene therapy, the trial design is to primarily ensure that treatment with TT-034 is safe, hence the gradual dose escalation.
For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.
| Company | Investor relations |
| Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com |
Kyahn Williamson Buchan Consulting Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au |
About Benitec Biopharma Limited:
Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX: BLT; OTC: BTEBD) which has developed a patented gene-silencing technology called ddRNAi or ‘expressed RNAi'. Based in Sydney, Australia with labs in Hayward CA (USA) and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Hepatitis C and B, drug resistant lung cancer and wet Age-related Macular Degeneration. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa. For more information visit www.benitec.com.
| © Copyright 1996-2019 irasia.com Ltd. All rights reserved. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |